BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted the company’s broad presence at the upcoming 106th Annual Meeting of the American Association for Cancer Research (AACR) being held April 18 to 22, 2015 in Philadelphia, PA, including eight abstracts on antibody-drug conjugate (ADC) technology and first preclinical data from a new immuno-oncology antibody utilizing sugar-engineered antibody (SEA) technology. Preclinical abstracts accepted for presentation include data in support of SGN-CD19A and SGN-CD70A, and activation of immune cells by SEA-CD40 and ADCETRIS (brentuximab vedotin).
Help employers find you! Check out all the jobs and post your resume.
